NCT02246634 (SERENADE) is a NA clinical trial of Diffusion Weighted MRI scan in Colorectal Neoplasms, sponsored by Imperial College London.

Who is sponsoring NCT02246634?

NCT02246634 is sponsored by Imperial College London.

What drugs are being tested in NCT02246634?

Interventions in NCT02246634: Diffusion Weighted MRI scan.

What condition does NCT02246634 study?

NCT02246634 studies Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms.

Is NCT02246634 still recruiting?

NCT02246634 is currently recruiting now. Last updated 16 October 2024.

Last reviewed 2024-10-16 · How we verify

NCT02246634: SERENADE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.

Recruiting now NA Last updated 16 October 2024

What this trial tests

NA trial testing Diffusion Weighted MRI scan in Colorectal Neoplasms in 282 participants. Currently enrolling.

Timeline

1 August 2014

Primary endpoint
1 December 2026

1 December 2031

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	282
Start date	1 August 2014
Primary completion	1 December 2026
Estimated completion	1 December 2031
Sites	13 locations across United Kingdom

Drugs / interventions tested

Diffusion Weighted MRI scan

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Neoplasm Metastases — all drugs for Neoplasm Metastases →
Hepatic Neoplasms — all drugs for Hepatic Neoplasms →

Sponsor

Imperial College London

Who can join

16 and older, any sex, with Colorectal Neoplasms or Neoplasm Metastases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
Time frame: 5 years after last recruit (end of trial)
Proportion of additional patients diagnosed with liver metastases on DW MRI compared with CT.

Sponsor's own description

Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years. Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future.
Thompson AAR, Wilkins MR, Wild JM, Kiely DG, et al · · 2020 · cited 1× · PMID 32373616 · DOI 10.3389/fmed.2020.00125

Verify or expand the search:

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02246634 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 16 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02246634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing